T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity

(2011) S. D. Gillies et al.   CLINICAL CANCER RESEARCH

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma

(2010) Sandra Rauser et al.   BMC CANCER

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients

(2010) Vanessa Deschoolmeester et al.   BMC IMMUNOLOGY

CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy

(2010) Yuchun Cao et al.   CLINICAL IMMUNOLOGY

Impact of 3 Different Short-term Chemotherapy Regimens on Lymphocyte-depletion and Reconstitution in Melanoma Patients

(2010) Julien Laurent et al.   JOURNAL OF IMMUNOTHERAPY

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review

(2010) Katsuhiko Nosho et al.   JOURNAL OF PATHOLOGY

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes

(2009) M Stumpf et al.   BRITISH JOURNAL OF CANCER

Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2

(2009) T. Kottke et al.   CLINICAL CANCER RESEARCH

Mechanisms of Tumor Cell Necrosis

(2009) Sergey Proskuryakov et al.   CURRENT PHARMACEUTICAL DESIGN

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

(2009) Antoni Ribas et al.   Journal of Translational Medicine

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

(2009) Mehmet Aliustaoglu et al.   MEDICAL ONCOLOGY

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

(2008) Jacob A. Klapper et al.   CANCER

Apoptosis and non-apoptotic deaths in cancer development and treatment response

(2008) Elza C. de Bruin et al.   CANCER TREATMENT REVIEWS

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

(2008) F. O. Smith et al.   CLINICAL CANCER RESEARCH

IL-2 Family of Cytokines in T Regulatory Cell Development and Homeostasis

(2008) Thomas R. Malek et al.   JOURNAL OF CLINICAL IMMUNOLOGY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology

Recent advances in cell-penetrating, non-peptide molecular carriers

(2007) Sung-Kee Chung et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS